Clinical trials: Fibrodysplasia Ossificans Progressiva, active
Fibrodysplasia Ossificans Progressiva
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally…
- Trial name
- FOPal (NCT06089616)
- Where
- 5 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Ipsen
Fibrodysplasia Ossificans Progressiva (FOP)
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia…
- Trial name
- Progress (NCT05090891)
- Testing
- INCB000928
- Where
- 24 sites in United States, Argentina and 15 more
- Volunteers
- 98 people
- Sponsor
- Incyte Corporation
Fibrodysplasia Ossificans Progressiva, FOP
A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)
This study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on children and adolescent participants with FOP.
- Trial name
- OPTIMA-2 (NCT07559513)
- Testing
- garetosmab
- Volunteers
- 18 people
- Sponsor
- Regeneron Pharmaceuticals
Fibrodysplasia Ossificans Progressiva
Saracatinib Trial TO Prevent FOP
This is a phase 2 study, designed as a European multicentre 6-month double blind random-ized controlled trial (RCT) of AZD0530 versus matched placebo, followed by a 12 month trial comparing open-label extended AZD0530 treatment…
- Trial name
- STOPFOP (NCT04307953)
- Testing
- AZD0530 Difumarate
- Where
- 3 sites in Germany, Netherlands and 1 more
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
Fibrodysplasia Ossificans Progressiva (FOP)
IL1 Inhibition in FOP
This is an observational pre-post study to observe if the off label use of anti-IL1 therapies, such as anakinra or canakinumab, can block ACVR1-induced flare activity and heterotopic ossification in FOP.
- Trial name
- NCT06724562
- Testing
- Anti-IL1 Therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco
Fibrodysplasia Ossificans Progressiva
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP).
- Trial name
- OPTIMA (NCT05394116)
- Testing
- Garetosmab
- Where
- 22 sites in United States, Australia and 16 more
- Volunteers
- 63 people
- Sponsor
- Regeneron Pharmaceuticals
Fibrodysplasia Ossificans Progressiva (FOP)
The Fibrodysplasia Ossificans Progressiva (FOP) Registry
The Fibrodysplasia Ossificans Progressiva (FOP) Registry is a global, non-interventional, voluntary database that captures demographic and disease data directly from FOP patients and their caregivers via a secure, web-based…
- Trial name
- NCT02745158
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- The International FOP Association
Fibrodysplasia Ossificans Progressiva
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
This study is researching an experimental drug called andecaliximab. The study will include pediatric and adult patients with fibrodysplasia ossificans progressiva (FOP).
- Trial name
- ANDECAL (NCT06508021)
- Testing
- Andecaliximab
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- Ashibio Inc